30 closest matches · ranked by relevance
Recurrent Lung Non-Small Cell Carcinoma · Stage IV Non-Small Cell Lung Cancer AJCC v7
Primary: Progression-free Survival (PFS) — 14.2; 4.4 Months
Non-Small-Cell Lung Carcinoma · Liver Cancer · Adrenal Cancer
Primary: Progression-free Survival — 11.2 months
Non-small Cell Lung Cancer
Primary: Progression Free Survival (PFS) at 18-month — 65.5; 66.3 Percentage of participants
Carcinoma, Non-Small-Cell Lung
Primary: Best Disease Response After a Maximum of Six Cycles. — 0; 23; 23; 6 Participants
Lung Cancer
Primary: Progression-free Survival — 12.6 months
Metastatic Lung Cancer · Stage IV Lung Cancer
Primary: Number of Participants With Progression-free Survival (PFS) After Completion of First Line Standard of Care Systemic Therapy — 1; 0 Participants
Non Small Cell Lung Cancer
Primary: Overall Survival — 26.81; 24.97 months — p=0.831
Extensive Stage Lung Small Cell Carcinoma · Recurrent Lung Small Cell Carcinoma
Primary: Progression-free Survival (PFS) — 5.5; 4.9 months — p=0.17
Lung Cancer
Primary: Boost Dose Toxicity — 5 Participants
Adenocarcinoma of the Lung · Adenosquamous Cell Lung Cancer · Bronchoalveolar Cell Lung Cancer
Primary: Time to Progression — 4.63 months
Lung Cancer
Primary: Maximum Dose of Erlotinib When Given Together With Carboplatin, Paclitaxel, and Thoracic Conformal Radiotherapy (Phase I [Closed to Accrual as of 1/3/2008]) — 0; 0; 2 DLTs
Stage IV Non-Small Cell Lung Cancer
Primary: Change in Quality of Life (QOL), Assessed by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (QLQ-C30) and QLQ-Lung…
Metastatic Lung Non-Squamous Non-Small Cell Carcinoma · Recurrent Lung Non-Squamous Non-Small Cell Carcinoma · Stage IV Lung Non-Small Cell Cancer AJCC v7
Primary: Progression-free Survival (PFS) — 6.35; 14.3 months
Lung Cancer
Primary: Median Progression Free Survival — 7.8 Months
Metastatic Malignant Neoplasm in the Brain · Recurrent Non-Small Cell Lung Carcinoma · Stage IIA Non-Small Cell Lung Carcinoma
Primary: Metabolic Response of All Pulmonary Lesions and Thoracic Lymph Nodes — 24 Participants
Lung Cancer
Primary: Overall Survival — 6.83; 6.31 Months — p=0.506
Non-Small Cell Lung Cancer
Primary: Survival Without Grade 3 or 4 Toxicity — 3.2; 0.7 months — p=<0.001
Lung Cancer
Primary: Mediastinal Nodal Clearance After Completion of Induction Chemoradiotherapy With or Without Panitumumab. — 68.2; 48.7 percentage of participants — p=0.96
Lung Cancer
Primary: Progression-free Survival at 6 Months — 60 percentage of participants
Non Small Cell Lung Cancer
Primary: Overall Survival Time (OS) — 11.5; 9.9 Months — p=0.0120
Small Cell Lung Cancer · Extensive Stage Lung Cancer · Chemonaive
Primary: Number of Participants Experiencing Dose Limiting Toxicity Regimen A - Phase I — 0; 1; 1 participants
Lung Cancer
Primary: 18 Month Survival — 58; 54 percentage of participants
Recurrent Non-small Cell Lung Cancer · Stage IIIB Non-small Cell Lung Cancer · Stage IV Non-small Cell Lung Cancer
Primary: Objective Response Rate (CR or PR) According to RECIST Criteria — 5 percentage of patients responding
Stage I Lung Non-Small Cell Cancer AJCC v7 · Stage IA Lung Non-Small Cell Carcinoma AJCC v7 · Stage IB Lung Non-Small Cell Carcinoma AJCC v7
Primary: Major Pathologic Response (mPR) — 5; 8; 7; 11 Participants
Non Small Cell Lung Cancer
Primary: Progression Free Survival — 77.1 percentage of participants
Lung Cancer
Primary: Overall Response Rate Defined as Complete or Partial Response as Assessed by RECIST Version 1.0 Criteria. — 38.1; 0 percentage of patients
Stage IIIB Lung Non-Small Cell Cancer AJCC v7 · Stage IV Non-Small Cell Lung Cancer AJCC v7
Primary: Progression Free Survival (PFS) — 4.3; 2.6 months — p=0.0006
Non-Small-Cell Lung Carcinoma
Primary: Response Rate — 6 percentage of participants
Non-Small Cell Lung Cancer
Primary: Overall Survival — 21.5; 24.1 Months — p=0.883
Non Small Cell Lung Cancer
Primary: 3-Year Overall Survival Rate — 45 percentage of participants